Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro

Journal of Lipid Research

Volumn 54, Issue 2, 2013, Pages 310-324

  Canfrań Duque, Alberto ^a   Casado, María E ^a   Pastor, Óscar ^b   Sánchez Wandelmer, Jana ^a   De La Penã, Gema ^a   Lerma, Milagros ^a   Mariscal, Paloma ^a   Bracher, Franz ^c   Lasunción, Miguel A ^a,d   Busto, Rebeca ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Apolipoprotein B secretion; Cholesterol biosynthesis; Intracellular lipid traffic; Lipid synthesis; Second generation antipsychotic drugs

Indexed keywords

APOLIPOPROTEIN B; CLOZAPINE; HALOPERIDOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; RISPERIDONE; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRIACYLGLYCEROL; ZIPRASIDONE;

ARTICLE; CELL METABOLISM; CELL STRAIN HEPG2; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; FATTY ACID METABOLISM; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; INTRACELLULAR TRANSPORT; METABOLIC INHIBITION; PRIORITY JOURNAL; PROTEIN SECRETION;

ACETATES; ANTIPSYCHOTIC AGENTS; APOLIPOPROTEIN B-100; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CHOLESTEROL; CHOLESTEROL, LDL; FATTY ACIDS; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; INTRACELLULAR SPACE;

EID: 84872440215     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M026948     Document Type: Article

References (58)

1. Miyamoto, S., G. E. Duncan, C. E. Marx, and J. A. Lieberman. 2005. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry. 10: 79-104. (Pubitemid 40139590)
2. Lieberman, J. A., T. S. Stroup, J. P. McEvoy, M. S. Swartz, R. A. Rosenheck, D. O. Perkins, R. S. Keefe, S. M. Davis, C. E. Davis, B. D. Lebowitz, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353: 1209-1223. (Pubitemid 41345943)
3. de Leon, J., M. T. Susce, M. Johnson, M. Hardin, L. Pointer, G. Ruano, A. Windemuth, and F. J. Diaz. 2007. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr. Res. 92: 95-102. (Pubitemid 46561228)
4. Gebhardt, S., M. Haberhausen, M. Heinzel-Gutenbrunner, N. Gebhardt, H. Remschmidt, J. C. Krieg, J. Hebebrand, and F. M. Theisen. 2009. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J. Psychiatr. Res. 43: 620-626.
5. Correll, C. U. 2007. Acute and long-term adverse effects of antipsychotics. CNS Spectr. 12: 10-14.
6. Newcomer, J. W. 2007. Antipsychotic medications: metabolic and cardiovascular risk. J. Clin. Psychiatry. 68 (Suppl 4) : 8-13. (Pubitemid 46762118)
7. Meyer, J. M., V. G. Davis, J. P. McEvoy, D. C. Goff, H. A. Nasrallah, S. M. Davis, G. L. Daumit, J. Hsiao, M. S. Swartz, T. S. Stroup, et al. 2008. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr. Res. 103: 104-109.
8. Meyer, J. M., and C. E. Koro. 2004. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 70: 1-17. (Pubitemid 38916622)
9. Lindenmayer, J. P., P. Czobor, J. Volavka, L. Citrome, B. Sheitman, J. P. McEvoy, T. B. Cooper, M. Chakos, and J. A. Lieberman. 2003. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am. J. Psychiatry. 160: 290-296. (Pubitemid 41110454)
10. Correll, C. U., P. Manu, V. Olshanskiy, B. Napolitano, J. M. Kane, and A. K. Malhotra. 2009. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 302: 1765-1773.
11. Smith, R. C., J. P. Lindenmayer, Q. Hu, E. Kelly, T. F. Viviano, J. Cornwell, S. Vaidhyanathaswamy, S. Marcovina, and J. M. Davis. 2010. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study. Schizophr. Res. 120: 204-209.
12. Vik-Mo, A. O., A. B. Birkenaes, J. Ferno, H. Jonsdottir, O. A. Andreassen, and V. M. Steen. 2008. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int. J. Neuropsychopharmacol. 11: 679-684. (Pubitemid 351931824)
13. Skrede, S., J. Ferno, M. J. Vazquez, S. Fjaer, T. Pavlin, N. Lunder, A. Vidal-Puig, C. Dieguez, R. K. Berge, M. Lopez, et al. 2012. Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int. J. Neuropsychopharmacol. 15: 163-179.
14. Summerly, R., and H. J. Yardley. 1965. The effect of a substituted fluorobutyrophenone(haloperidol) on the metabolism of sterols in rat skin. Biochem. J. 96: 30.
15. Sánchez-Wandelmer, J., A. M. Hernández-Pinto, S. Cano, A. Dávalos, G. de la Peña, L. Puebla-Jiménez, E. Arilla-Ferreiro, M. A. Lasunción, and R. Busto. 2009. Effects of the antipsychotic drug haloperidol on the somastostatinergic system in SH-SY5Y neuroblastoma cells. J. Neurochem. 110: 631-640.
16. Sánchez-Wandelmer, J., A. Dávalos, G. de la Peña, S. Cano, M. Giera, A. Canfrán-Duque, F. Bracher, A. Martín-Hidalgo, C. Fernández-Hernando, M. A. Lasunción, et al. 2010. Haloperidol disrupts lipid rafts and impairs insulin signaling in SH-SY5Y cells. Neuroscience. 167: 143-153.
17. Kristiana, I., L. J. Sharpe, V. S. Catts, L. H. Lutze-Mann, and A. J. Brown. 2010. Antipsychotic drugs upregulate lipogenic gene expression by disrupting intracellular trafficking of lipoprotein-derived cholesterol. Pharmacogenomics J. 10: 396-407.
18. Lauressergues, E., B. Staels, K. Valeille, Z. Majd, D. W. Hum, P. Duriez, and D. Cussac. 2010. Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. Naunyn Schmiedebergs Arch. Pharmacol. 381: 427-439.
19. Lauressergues, E., F. Martin, A. Helleboid, E. Bouchaert, D. Cussac, R. Bordet, D. Hum, G. Luc, Z. Majd, B. Staels, et al. 2011. Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver. Naunyn Schmiedebergs Arch. Pharmacol. 383: 423-436.
20. Lange, Y., J. Ye, and T. L. Steck. 1998. Circulation of cholesterol between lysosomes and the plasma membrane. J. Biol. Chem. 273: 18915-18922. (Pubitemid 28366279)
21. Kedjouar, B., P. de Medina, M. Oulad-Abdelghani, B. Payre, S. Silvente-Poirot, G. Favre, J. C. Faye, and M. Poirot. 2004. Molecular characterization of the microsomal tamoxifen binding site. J. Biol. Chem. 279: 34048-34061. (Pubitemid 39063057)
22. Suárez, Y., C. Fernández, D. Gómez-Coronado, A. J. Ferruelo, A. Dávalos, J. Martínez-Botas, and M. A. Lasunción. 2004. Synergistic upregulation of low-density lipoprotein receptor activity by tamoxifen and lovastatin. Cardiovasc. Res. 64: 346-355. (Pubitemid 39361697)
23. Ferno, J., M. B. Raeder, A. O. Vik-Mo, S. Skrede, M. Glambek, K. J. Tronstad, H. Breilid, R. Lovlie, R. K. Berge, C. Stansberg, et al. 2005. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J. 5: 298-304. (Pubitemid 41486229)
24. Ferno, J., S. Skrede, A. O. Vik-Mo, B. Havik, and V. M. Steen. 2006. Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci. 7: 69.
25. Polymeropoulos, M. H., L. Licamele, S. Volpi, K. Mack, S. N. Mitkus, E. D. Carstea, L. Getoor, A. Thompson, and C. Lavedan. 2009. Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia. Schizophr. Res. 108: 134-142.
26. Martínez-Botas, J., A. J. Ferruelo, Y. Suárez, C. Fernández, D. Gómez-Coronado, and M. A. Lasunción. 2001. Dose-dependent effects of lovastatin on cell cycle progression. Distinct requirement of cholesterol and non-sterol mevalonate derivatives. Biochim. Biophys. Acta. 1532: 185-194. (Pubitemid 32706438)
27. Calvo, D., D. Gómez-Coronado, Y. Suárez, M. A. Lasunción, and M. A. Vega. 1998. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J. Lipid Res. 39: 777-788. (Pubitemid 28163280)
28. Fernández, C., M. Martín, D. Gómez-Coronado, and M. A. Lasunción. 2005. Effects of distal cholesterol biosynthesis inhibitors on cell proliferation and cell cycle progression. J. Lipid Res. 46: 920-929.
29. Giera, M., F. Plossl, and F. Bracher. 2007. Fast and easy in vitro screening assay for cholesterol biosynthesis inhibitors in the post-squalene pathway. Steroids. 72: 633-642. (Pubitemid 46978408)
30. Meex, S. J., U. Andreo, J. D. Sparks, and E. A. Fisher. 2011. Huh-7 or HepG2 cells: which is the better model for studying human apo-lipoprotein-B100 assembly and secretion? J. Lipid Res. 52: 152-158.
31. Horton, J. D., J. L. Goldstein, and M. S. Brown. 2002. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109: 1125-1131. (Pubitemid 34496588)
32. Silve, S., P. H. Dupuy, C. Labit-Lebouteiller, M. Kaghad, P. Chalon, A. Rahier, M. Taton, J. Lupker, D. Shire, and G. Loison. 1996. Emopamil-binding protein, a mammalian protein that binds a series of structurally diverse neuroprotective agents, exhibits delta8-delta7 sterol isomerase activity in yeast. J. Biol. Chem. 271: 22434-22440. (Pubitemid 26304678)
33. Kelley, R. I., and R. C. Hennekam. 2000. The Smith-Lemli-Opitz syndrome. J. Med. Genet. 37: 321-335. (Pubitemid 30261263)
34. Tuck, S. F., H. Patel, E. Safi, and C. H. Robinson. 1991. Lanosterol 14 alpha-demethylase (P45014DM): effects of P45014DM inhibitors on sterol biosynthesis downstream of lanosterol. J. Lipid Res. 32: 893-902.
35. Rahier, A., and M. Taton. 1996. Sterol biosynthesis: strong inhibition of maize delta 5,7-sterol delta 7-reductase by novel 6-aza-B-homosteroids and other analogs of a presumptive carbocationic intermediate of the reduction reaction. Biochemistry. 35: 7069-7076.
36. Alves, I., G. Staneva, C. Tessier, G. F. Salgado, and P. Nuss. 2011. The interaction of antipsychotic drugs with lipids and subsequent lipid reorganization investigated using biophysical methods. Biochim. Biophys. Acta. 1808: 2009-2018.
37. Oruch, R., E. Hodneland, I. F. Pryme, and H. Holmsen. 2008. Psychotropic drugs interfere with the tight coupling of polyphosphoinositide cycle metabolites in human platelets: a result of receptor-independent drug intercalation in the plasma membrane? Biochim. Biophys. Acta. 1778: 2165-2176.
38. Oruch, R., A. Lund, I. F. Pryme, and H. Holmsen. 2010. An intercalation mechanism as a mode of action exerted by psychotropic drugs: results of altered phospholipid substrate availabilities in membranes? J. Chem. Biol. 3: 67-88.
39. Fitzky, B. U., F. F. Moebius, H. Asaoka, H. Waage-Baudet, L. Xu, G. Xu, N. Maeda, K. Kluckman, S. Hiller, H. Yu, et al. 2001. 7-Dehydrocholesterol- dependent proteolysis of HMG-CoA reductase suppresses sterol biosynthesis in a mouse model of Smith-Lemli-Opitz/RSH syndrome. J. Clin. Invest. 108: 905-915. (Pubitemid 32880299)
40. Rodriguez-Acebes, S., P. de la Cueva, C. Fernandez-Hernando, A. J. Ferruelo, M. A. Lasuncion, R. B. Rawson, J. Martinez-Botas, and D. Gomez-Coronado. 2009. Desmosterol can replace cholesterol in sustaining cell proliferation and regulating the SREBP pathway in a sterol-Delta24-reductase- deficient cell line. Biochem. J. 420: 305-315.
41. Ferno, J., A. O. Vik-Mo, G. Jassim, B. Havik, K. Berge, S. Skrede, O. A. Gudbrandsen, J. Waage, N. Lunder, S. Mork, et al. 2009. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology (Berl.). 203: 73-84.
42. Ginsberg, H. N., Y. L. Zhang, and A. Hernandez-Ono. 2005. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch. Med. Res. 36: 232-240. (Pubitemid 40755136)
43. Vik-Mo, A. O., J. Ferno, S. Skrede, and V. M. Steen. 2009. Psychotropic drugs up-regulate the expression of cholesterol transport proteins including ApoE in cultured human CNS- and liver cells. BMC Pharmacol. 9: 10.
44. Choi, H. Y., B. Karten, T. Chan, J. E. Vance, W. L. Greer, R. A. Heidenreich, W. S. Garver, and G. A. Francis. 2003. Impaired ABCA1-dependent lipid efflux and hypoalphalipoproteinemia in human Niemann-Pick type C disease. J. Biol. Chem. 278: 32569-32577. (Pubitemid 37059094)
45. Garver, W. S., D. Jelinek, J. N. Oyarzo, J. Flynn, M. Zuckerman, K. Krishnan, B. H. Chung, and R. A. Heidenreich. 2007. Characterization of liver disease and lipid metabolism in the Niemann-Pick C1 mouse. J. Cell. Biochem. 101: 498-516. (Pubitemid 46705306)
46. Perez-Iglesias, R., B. Crespo-Facorro, J. A. Amado, M. T. Garcia-Unzueta, M. L. Ramirez-Bonilla, C. Gonzalez-Blanch, O. Martinez-Garcia, and J. L. Vazquez-Barquero. 2007. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J. Clin. Psychiatry. 68: 1733-1740. (Pubitemid 350247503)
47. Albaugh, V. L., R. Singareddy, D. Mauger, and C. J. Lynch. 2011. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS ONE. 6: e22662.
48. Goldman, S. D., R. S. Funk, R. A. Rajewski, and J. P. Krise. 2009. Mechanisms of amine accumulation in, and egress from, lysosomes. Bioanalysis. 1: 1445-1459.
49. Daniel, W. A., and J. Wojcikowski. 1997. Contribution of lysosomal trapping to the total tissue uptake of psychotropic drugs. Pharmacol. Toxicol. 80: 62-68. (Pubitemid 27078228)
50. Daniel, W. A., and J. Wojcikowski. 1999. Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants. Eur. Neuropsychopharmacol. 9: 483-491. (Pubitemid 30089061)
51. Liscum, L., and J. R. Faust. 1989. The intracellular transport of low density lipoprotein-derived cholesterol is inhibited in Chinese hamster ovary cells cultured with 3-beta-[2-(diethylamino)ethoxy] androst-5-en-17-one. J. Biol. Chem. 264: 11796-11806. (Pubitemid 19185347)
52. Liscum, L. 1990. Pharmacological inhibition of the intracellular transport of low-density lipoprotein-derived cholesterol in Chinese hamster ovary cells. Biochim. Biophys. Acta. 1045: 40-48. (Pubitemid 20205782)
53. Lange, Y., and T. L. Steck. 1994. Cholesterol homeostasis. Modulation by amphiphiles. J. Biol. Chem. 269: 29371-29374. (Pubitemid 24365077)
54. Liscum, L., and N. K. Dahl. 1992. Intracellular cholesterol transport. J. Lipid Res. 33: 1239-1254.
55. Underwood, K. W., B. Andemariam, G. L. McWilliams, and L. Liscum. 1996. Quantitative analysis of hydrophobic amine inhibition of intracellular cholesterol transport. J. Lipid Res. 37: 1556-1568. (Pubitemid 26249985)
56. Cenedella, R. J. 2009. Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids. 44: 477-487.
57. Duriatti, A., P. Bouvier-Nave, P. Benveniste, F. Schuber, L. Delprino, G. Balliano, and L. Cattel. 1985. In vitro inhibition of animal and higher plants 2,3-oxidosqualene-sterol cyclases by 2-aza-2,3-dihydrosqualene and derivatives, and by other ammonium-containing molecules. Biochem. Pharmacol. 34: 2765-2777. (Pubitemid 15041763)
58. Bae, S. H., and Y. K. Paik. 1997. Cholesterol biosynthesis from lanosterol: development of a novel assay method and characterization of rat liver microsomal lanosterol delta 24-reductase. Biochem. J. 326: 609-616.